HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Market News: DXM Sales Age-Restriction Bill Filed, E-Cigarettes Top NRTs In UK Trial

Executive Summary

Resp. Matsui, Johnson again introduce bill for national age-18 requirement for OTC DXM sales; E-Cigarettes top NRTs for smoking cessation efficacy in UK trial.

You may also be interested in...



Another State Age-Restricts Sales Of DXM OTC Drugs As Teens' Abuse Of Ingredient Grows

Percentage of 10th- and 12th-graders in MTF survey using DXM-containing OTCs for inebriation effects had declined while rate of 8th-graders increased from 2018 to 2019. However, abuse of OTC drugs containing the cough suppressant increased in all age groups in 2020 survey.

HBW Legislative News: Another Federal CR, Michigan On DXM List, Senators Say Supplements Are 'Medical Expenses'

Federal agencies at FY 2019 funding for another month; Michigan imposes age restriction on OTC DXM sales; and senators urge IRS to make supplements 'medical expenses'.

Long-term E-cigarette Use Could Spark More Smoking, French Study Suggests

Research in JAMA Internal Medicine studied "longitudinal associations between [e-cigarette] use and tobacco smoking patterns in a large population-based cohort study" and found use was associated with reduction in smoking and an increased probability of smoking cessation. But the researchers saw that e-cigarette users who quit tobacco "tended to relapse to smoking more frequently than" former smokers who didn't use e-cigarettes.

Related Content

Topics

UsernamePublicRestriction

Register

RS148486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel